- Home
- GMAB vs USFD Comparison
GMAB vs USFD Comparison
Compare GMAB & USFD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- USFD
- Stock Information
- Founded
- GMAB 1999
- USFD 2007
- Country
- GMAB Denmark
- USFD United States
- Employees
- GMAB N/A
- USFD N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- USFD Food Distributors
- Sector
- GMAB Health Care
- USFD Consumer Discretionary
- Exchange
- GMAB Nasdaq
- USFD Nasdaq
- Market Cap
- GMAB 15.4B
- USFD 17.5B
- IPO Year
- GMAB N/A
- USFD 2016
- Fundamental
- Price
- GMAB $28.61
- USFD $79.89
- Analyst Decision
- GMAB Buy
- USFD Strong Buy
- Analyst Count
- GMAB 6
- USFD 10
- Target Price
- GMAB $37.60
- USFD $88.20
- AVG Volume (30 Days)
- GMAB 1.4M
- USFD 1.8M
- Earning Date
- GMAB 11-05-2025
- USFD 11-06-2025
- Dividend Yield
- GMAB N/A
- USFD N/A
- EPS Growth
- GMAB 77.72
- USFD 10.81
- EPS
- GMAB 21.62
- USFD 2.33
- Revenue
- GMAB $3,646,881,232.00
- USFD $38,652,000,000.00
- Revenue This Year
- GMAB $22.68
- USFD $6.63
- Revenue Next Year
- GMAB $15.85
- USFD $6.24
- P/E Ratio
- GMAB $1.32
- USFD $34.30
- Revenue Growth
- GMAB 32.97
- USFD 5.32
- 52 Week Low
- GMAB $17.24
- USFD $56.65
- 52 Week High
- GMAB $28.74
- USFD $85.11
- Technical
- Relative Strength Index (RSI)
- GMAB 81.36
- USFD 57.33
- Support Level
- GMAB $27.58
- USFD $76.03
- Resistance Level
- GMAB $27.61
- USFD $78.41
- Average True Range (ATR)
- GMAB 0.37
- USFD 1.30
- MACD
- GMAB 0.26
- USFD 0.27
- Stochastic Oscillator
- GMAB 97.02
- USFD 96.26
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About USFD US Foods Holding Corp.
US Foods Holding Corp is the U.S. food service distributor that distributes food and nonfood products to the healthcare and hospitality industries, restaurants, and education, government facilities, and grocers. It has nearly 250,000 restaurants and foodservice operators with more than 70 locations that provide customers with food offering and a comprehensive suite of e-commerce, technology, and business solutions. The company operates in one business segment in which it markets, sells and distributes fresh, frozen and dry food and non-food products to foodservice customers throughout the U.S.